The Company

We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.

Scientific and Medical

Focus on discovering and developing therapies for patients with cancer in areas of unmet need

Initial program: genetic therapy for early stage bladder cancer

Utilizes technology licensed from Hebrew University

Corporate

Founded in 2004; based in Cambridge and Jerusalem

CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure

Financial

$39 million (end 2018)
Approximate market capitalization

ADSs, each representing five ordinary shares, publicly traded on Nasdaq (NASDAQ:ANCN)

Ordinary shares, no par value, publicly traded on the TASE (TASE:ANCN)

37.1 million outstanding shares, equivalent to 7.4 million ADSs

50.5 million shares fully diluted, equivalent to 10.1 million ADSs

$7.5 million (end 2018)
cash, no debt

Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now (link to ClinicalTrials.gov).

We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq and Tel Aviv Stock Exchange (NASDAQ/TASE: ANCN).

Our R&D activities build upon the discovery by Professor Avraham Hochberg, of the Hebrew University of Jerusalem, of the human H19 gene. It has been shown that the gene is expressed in over forty different forms of cancer, including especially bladder cancer, while being quiescent in most normal adult tissues. H19-based therapy is designed to be a highly selective method of killing cancer cells that spares normal bladder tissue.

Our Mission

We are dedicated to the discovery, development and commercialization of effective and safe treatments for cancer that address significant unmet medical needs and provide clinical benefits to millions of patients worldwide.

Our Core Values

  • Scientific Achievement – we are dedicated to the highest level of scientific innovation and research, while maintaining the strictest standards of ethics and integrity.
  • Compassion – we value life and we devote our resources to its preservation and improvement.
  • Excellence in Execution – we set aggressive goals with confidence in our ability and perseverance to achieve them.
  • Creating Value – we are committed to the creation of value for the patient we serve, the societies we inhabit and the shareholders who believe in us.